Madrigal Pharmaceuticals Posts Wider Loss In Q1

Madrigal Pharmaceuticals reported a first-quarter net loss of $94.4 million, or $3.25 per share, wider than the $73.2 million loss, or $2.61 per share, a year earlier. The larger loss points to continued negative earnings fundamentals, though the brief release provides no guidance or revenue details. The update is likely to be a modest stock-specific headwind rather than a sector-wide catalyst.

Analysis

Madrigal Pharmaceuticals reported a first-quarter net loss of $94.4 million, or $3.25 per share, wider than the $73.2 million loss, or $2.61 per share, a year earlier. The larger loss points to continued negative earnings fundamentals, though the brief release provides no guidance or revenue details. The update is likely to be a modest stock-specific headwind rather than a sector-wide catalyst.